Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Renamezin vs Kremezin in Pre-dialysis Chronic Renal Failure
NCT02681952Phase 4Completed
- Sponsor
- Daewon Pharm
- Start
- Dec 2015
- Primary completion
- Dec 2016
- Modality
- Inorganic Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of Renamezin in chronic kidney disease (CKD) (2 arms), sponsored by Daewon Pharm. Primary endpoint: Preference of formulation at 24 weeks. Started Dec 2015; status: completed.
02
Drugs
Renamezin
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT02681952.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02681952.